Hope Biosciences Research Foundation

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Hope Biosciences Research Foundation sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 6 completed early-phase tilt top decile by trial count

Hope Biosciences Research Foundation: 9 sponsored US clinical trials, 1 recruiting.

Hope Biosciences Research Foundation sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson Disease, with 2 trials.

Top-decile sponsor footprint

Hope Biosciences Research Foundation ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

HB-adMSCs for the Treatment of Crohn's Disease

NCT07077746
ACTIVE NOT RECRUITING Phase 2

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

NCT06800404
COMPLETED Phase 2

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

NCT05126563
COMPLETED Phase 2

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540
COMPLETED Phase 2

Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

NCT04995081
COMPLETED Phase 2

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

NCT04928287
TERMINATED Phase 2

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

NCT04362189
COMPLETED Phase 2

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.

NCT04348435
COMPLETED Phase 2

A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19

NCT04349631

Phase Distribution

PhaseTrial count
Phase 2 9

Therapeutic Areas

Parkinson Disease 2
Post COVID-19 Syndrome 1
Crohn Disease (CD) 1
Relapsing-remitting Multiple Sclerosis (RRMS) 1
Multiple Sclerosis 1

What is open in the Hope Biosciences Research Foundation pipeline

1 recruiting of 9 indexed (11% open); 6 completed (67%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Parkinson Disease (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Hope Biosciences Research Foundation: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Hope Biosciences Research Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Hope Biosciences Research Foundation4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Hope Biosciences Research Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Hope Biosciences Research Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Hope Biosciences Research Foundation page

9 registered trials is a research-attention snapshot, not an endorsement of Hope Biosciences Research Foundation or any single study.

  • 1 of Hope Biosciences Research Foundation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Parkinson Disease is the condition Hope Biosciences Research Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Hope Biosciences Research Foundation pipeline card: 9 registered trials from official public datasets.Report a data error.